Skip to content

Curative Embolization of AVMs Based on Draining Vein Obliteration: A prospective study

Prospective study of Curative Embolization of bAVM Based on Draining Vein Obliteration

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17013851
Enrollment
Unknown
Registered
2017-12-11
Start date
2017-12-20
Completion date
Unknown
Last updated
2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Arteriovenous Malformations

Interventions

Transarterial embolization, microsurgical, stereotactic radiosurgery grope:Interventional embolization, resection, radiosurgery
Transvenous interventional embolization group:Interventional embolization

Sponsors

Henan Provincial People' Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 6-60 years old; 2. Nidus size = 6cm: CTA, MRA, and MRI were the most common diagnostic methods for Nidus, but the size of BAVM was determined by DSA; 3. Preoperative nidus has ruptured; arterial feeds is slender, tortuous and narrow; a main draining vein, which collects 80% blood of the nidus ,and the structure can be identified to make microcatheter enter the nidus through the vein; 4. Patients can tolerate hypotension; 5. Patients are willing to attend the study and the ability to regularly follow-up; 6. Patients can understand the study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients suffered from any of the following diseases: multiple BAVM, venous malformation,cavernous hemangioma, hereditary hemorrhagic telangiectasia,moyamoya ndisease; 2. Although the medical treatment,still can not tolerate general anesthesia; 3. Because of Vascular severe tortuosity or anatomical factors , arterial sheath, the guiding catheter is difficult to internal carotid artery or vertebral artery; 4. Thrombosis occurs in the vessel wall near the lesion or at the lesion site; 5. Severe allergy history of contrast agents or medical glue; 6. Active bleeding or coagulopathy, activated gastrointestinal ulcers, 30 days of systemic bleeding, platelet count 1.5, the bleeding time more than the upper limit of normal 1min or heparin associated thrombocytopenia more, severe hypertension hemorrhage risk not control (systolic pressure >180mmHg or diastolic pressure >115mmHg), severe liver injury: AST and ALT more than the normal 3 times, Cirrhosis and severe injury of renal function (creatinine >265.2 mol/L); 7. Within 30 days before or within 90 days of major surgery (including femoral artery, aorta or carotid artery surgery); 8. Failure to understand the contents of cooperative trials and to sign informed consents; 9. Severe dementia or mental disorders cannot be followed up; 10. Female patients during pregnancy; 11. Combined with other lesions, the patient expected survival for <3 years; 12. Other studies that have been included may be in conflict with current research.

Design outcomes

Primary

MeasureTime frame
Stroke;Size of nidus;

Countries

China

Contacts

Public ContactWeixing Bai

Henan Provincial People's Hospital

13526678722@126.com+86 13526678722

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 25, 2026